The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Maryland Oncology Hematology · Segeberger Kliniken · +5 more institutions
Abstract
PURPOSE: Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes. EXPERIMENTAL DESIGN: We used immunohistochemical profiles [human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-negative for HER2+/estrogen receptor-negative (ER-), hormone receptor and HER2- for basal-like, hormone receptor-positive for luminal] to subtype a prospectively maintained data set of patients with breast cancer treated with neoadjuvant anthracycline-based (doxorubicin plus cyclophosphamide, AC) chemotherapy. We analyzed each subtype for clinical and pathologic response to neoadjuvant…
Citation impact
- FWCI
- 47.03
- Percentile
- 100%
- References
- 22
Authors
10- LALisa A. CareyCorresponding
Maryland Oncology Hematology
- ECElizabeth Claire Dees
Maryland Oncology Hematology
- LSLynda Sawyer
Segeberger Kliniken, UNC Lineberger Comprehensive Cancer Center
- LGLisa Gatti
Segeberger Kliniken, UNC Lineberger Comprehensive Cancer Center
- DTDominic T. Moore
Cancer Research And Biostatistics, Segeberger Kliniken, Biostatistical Consulting (United States), UNC Lineberger Comprehensive Cancer Center
Topics & keywords
- Breast cancer
- Anthracycline
- Internal medicine
- Estrogen receptor
- Chemotherapy
- Oncology
- Medicine
- Progesterone receptor
- Good health and well-being